Tag: Patrys Ltd
BioCina launches manufacturing program for Patrys’ injectable delirium therapy
BioCina Pty Ltd, a global Contract Development and Manufacturing Organisation (CDMO), has launched a comprehensive manufacturing program for RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care.Â
Featured Article
Responding to manufacturing demand and performance signals
Australian manufacturers are navigating a challenging environment. Just as output had returned to growth, higher fuel and freight costs, rising input prices and global supply chain disruption renewed pressure on margins and cash flow.
